

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



(Please scan this QR code to view the RHP)

PRAMODINI MEDICARE LIMITED

CIN: U85110AP2000PLC035231

Our Company was originally incorporated on September 12, 2000 under the name “Pramodini Medicare Private Limited” under the provisions of the Companies Act, 1956 with the Registrar of Companies, Andhra Pradesh, Hyderabad. Thereafter, the status of our Company was changed to public limited Company and the name of our Company was changed to “Pramodini Medicare Limited” vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on October 30, 2025. The fresh certificate of incorporation consequent to conversion was issued on November 12, 2025 by the Centralised Processing Centre. The Corporate Identification Number of our Company is U85110AP2000PLC035231. For further details on Incorporation and Registered Office of our Company, see “History and Certain Corporate Matters” beginning on page 173 of the Red Herring Prospectus.

Registered Office: D. No: - 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India - 520002

Tel No: +91- 9985782727 | E-mail: investors@pramodinidiagnostics.com | Website: www.pramodinidiagnostics.com

Contact Person: Mr. Rushikesh Vijay Gosavi, Company Secretary and Compliance Officer

THE PROMOTERS OF OUR COMPANY ARE DR. CHALASANI KULDEEP KUMAR, DR. CHALASANI KAVITHA, MS. CHALASANI DURGA AASHRITHA, MS. CHALASANI LALITAKUMARI AND M/S. SRI RAM MEDICARE PRIVATE LIMITED.

“THE OFFER IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE (NSE EMERGE).”

THE OFFER

INITIAL PUBLIC OFFER OF UP TO 58,51,200* EQUITY SHARES OF FACE VALUE OF ₹10/- EACH (THE “EQUITY SHARES”) OF PRAMODINI MEDICARE LIMITED (“OUR COMPANY” OR “PRAMODINI” OR “THE OFFEROR”) AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [●] LAKHS COMPRISING OF FRESH OFFER OF UP TO 53,50,800 EQUITY SHARES AGGREGATING TO ₹ [●] LAKHS (“FRESH OFFER”) AND AN OFFER FOR SALE OF UP TO 5,00,400 EQUITY SHARES BY DR. CHALASANI KULDEEP KUMAR, DR. CHALASANI KAVITHA AND M/S. SRI RAM MEDICARE PRIVATE LIMITED (“PROMOTER SELLING SHAREHOLDERS”) AGGREGATING TO ₹ [●] LAKHS (“OFFER FOR SALE”) (“PUBLIC OFFER”). THE OFFER INCLUDES A RESERVATION OF UP TO 3,36,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH, AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKERS TO THE OFFER (THE “MARKET MAKER RESERVATION PORTION”). THE PUBLIC OFFER LESS MARKET MAKER RESERVATION PORTION I.E. NET OFFER OF UP TO 55,15,200 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH, AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET OFFER”. THE PUBLIC OFFER AND NET OFFER WILL CONSTITUTE 26.54% AND 25.02% RESPECTIVELY OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

*Subject to finalisation of basis of allotment.

DETAILS OF OFFER FOR SALE, PROMOTER SELLING SHAREHOLDERS AND THEIR WEIGHTED AVERAGE COST OF ACQUISITION:

Name	Type	No. Of Shares Offered/ Amount in ₹	WACA per Equity Share in (₹*)
Dr. Chalasani Kuldeep Kumar	Promoter Selling Shareholder	Up to 2,14,400 Equity Shares	6.99
Dr. Chalasani Kavitha	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares	6.23
M/s. Sri Ram Medicare Private Limited	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares	4.25

*As certified by Statutory Auditor of our Company, by way of their certificate dated August 03, 2026.

PRICE BAND: ₹ 110/- to ₹ 118/- PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH

THE FLOOR PRICE IS 11.00 TIMES THE FACE VALUE OF THE EQUITY SHARES AND
CAP PRICE IS 11.80 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FY 2025-26 AT THE FLOOR PRICE IS 10.57 TIMES AND AT THE CAP PRICE IS 11.34 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF 1,200 EQUITY SHARES AND IN MULTIPLES OF 1,200 EQUITY SHARES THEREAFTER.

ISSUE PROGRAM

ANCHOR BID OPENS ON: TUESDAY, AUGUST 11, 2026
OPENS ON: WEDNESDAY, AUGUST 12, 2026
CLOSES ON: FRIDAY, AUGUST 14, 2026

BRIEF DESCRIPTION OF THE BUSINESS OF THE OFFEROR

Our Company is a diagnostic service provider in India. We provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. The services offered at each location vary based on the scope agreed under the respective MOUs. We provide healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions Our diagnostic services include a comprehensive range of offerings: (i) “Radiology” which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, Dexa Scan and Intervention Radiology, (ii) “Clinical Laboratory” which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) “Nuclear Medicine” which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy. For more details, please refer chapter titled “Our Business” beginning on page 135 of the Red Herring Prospectus.

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON EMERGE PLATFORM OF NSE. FOR THE PURPOSE OF THE OFFER, THE DESIGNATED STOCK EXCHANGE SHALL BE NSE.

ALLOCATION OF THE ISSUE

QIB PORTION	NOT MORE THAN 50.00% OF THE NET OFFER
INDIVIDUAL INVESTOR PORTION	NOT LESS THAN 35.00% OF THE NET OFFER
NON-INSTITUTIONAL PORTION	NOT LESS THAN 15.00% OF THE NET OFFER
MARKET MAKER PORTION	UPTO 3,36,000 EQUITY SHARES OR 5.74% OF THE OFFER

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RED HERRING PROSPECTUS AND THE TERMS OF THE OFFER, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE OFFER AVAILABLE IN ANY MANNER.

The price band is justified based on the qualitative factors, quantitative factors and KPIs disclosed in the chapter title “Basis for Offer Price” beginning on page 106 of the Red Herring Prospectus.

RISKS TO INVESTORS

1. Risk to Investors: Summary description of key risk factors based on materiality, for details refer to Section titled “ Risk Factors” on page 24 of the Red Herring Prospectus:

The below mentioned risks are top 10 risk factors as per the Red Herring Prospectus:

- A significant portion of our revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect our business, financial condition and results of operations
- Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects
- We derive substantial portion of our revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on our business, results of operations and financial condition
- We are majorly dependent on certain key customers cum patients for a substantial portion of our revenues. Loss of relationship with any of these customers cum patients may have a material adverse effect on our profitability and results of operations
- We derive a significant portion of our revenue from government authorities (B2G). Any reduction in revenue from them or delays in payments by government authorities, may adversely affect our business, financial condition and results of operations
- Failure to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations
- We rely on our information technology systems in providing our diagnostic services and managing our operations, and any disruption to such systems or networks could adversely affect our business operations, reputation and financial performance
- Any inadequacy in packaging, collection of, or failure or delay in the delivery of, specimens to our diagnostic centres could compromise or destroy the integrity of such specimens, which could adversely affect our business, results of operations and financial condition
- Our Company is not having any exact comparable Indian peer which have similar business to our Company
- We are required to furnish bank guarantees as part of our business under Strategic Partnership with PSU Govt of India. Our inability to arrange such guarantees or the invocation of such guarantees may adversely affect our cash flows and financial condition.

2. Details of suitable ratios of our Company and our peer group for the latest full financial year:

Name of Company	CMP (₹)	Face Value (₹)	Basic & Diluted EPS (₹)	P / E Ratio (times)	RoNW (%)	NAV per Share (₹)
Pramodini Medicare Limited	[●]	10	10.41	[●]	32.69%	31.84
Peer Group						
Invicta Diagnostic Limited	66.75	10	4.90	13.62	9.76%	39.71
Krsnaa Diagnostics Limited	524.05	5	31.30	16.74	10.35%	302.23
Star Imaging & Path Labs Limited	87.00	10	11.05	7.87	16.58%	66.65

Source: www.nseindia.com and www.bseindia.com

Notes:

- The figures for our company are based on Restated Consolidated Financial Statements for the year ended March 31, 2026.
- P/E Ratio has been computed based on their respective closing market price on July 30, 2026, as divided by the Basic EPS as on March 31, 2026.
- Restated Profit for the year attributable to equity shareholders divided by Net Worth of our Company.
- Net asset value per equity share is calculated as net worth as of the end of relevant year divided by the weighted average number of equities shares outstanding at the end of the year.
- Price Earning (P/E) Ratio in relation to the Offer Price of [●] per share.
- The Price Band determined by our Company and the Promoter Selling Shareholders in consultation with the Book Running Lead Manager is justified by our Company in consultation with the Book Running Lead Manager on the basis of the above parameters.
- The peer group companies are not exactly comparable in all aspects of business and services that our Company provides.

3. Weighted Average Return on Net worth for the last 3 financial years (RoNW)

As per Restated Financial Statements:

Particulars	RoNW (%)	Weights
March 31, 2026	32.69%	3

(Continued next page...)

(Continued from previous page...)

March 31, 2025	30.83%	2
March 31, 2024	28.00%	1
Weighted Average	31.29%	

Note: Return on Net Worth (%) = Profit for the period/ year / Net Worth at the end of the period/year.

4. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI as applicable:

a) The price per share of our Company based on the primary/ new issue of shares (equity / convertible securities), excluding shares issued under ESOP/ ESOS and issuance of bonus shares

There has been no issuance of Equity Shares (excluding shares issued under ESOP/ESOS and issuance of bonus shares) during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-offer capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days.

b) The price per share of our Company based on the secondary sale / acquisition of shares (equity shares)

Except as mentioned below, there have been no secondary sale / acquisitions of Equity Shares, where the promoters, members of the promoter group, selling shareholder or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-offer share capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

Date of Transaction	Name of Transferor	Name of Transferee	Number of Equity Shares Acquired/sold	Acquisition/ Transfer Price (₹)	Total consideration (₹)
March 10, 2025	Dr. Chalasani Kuldeep Kumar	Mr. Yash Hitesh Patel	6,42,120	31/-	1,99,05,720
March 17, 2025		Ms. Sumita Mishra	2,56,840	31/-	79,62,040
The existing equity shares of face value of ₹1/- each were consolidated into equity shares of face value of ₹10/- each vide shareholders' resolution dated March 30, 2025.					
April 02, 2025	Dr. Chalasani Kuldeep Kumar	Mr. Siva Rama Krishna Prasad Atluri	6,451	310/-	1,99,98,10
April 02, 2025		Ms. Karri Mani Kumari	3,225	310/-	9,99,750
April 03, 2025		Mr. Swapnil Sudhakar Rao Topale	3,225	310/-	9,99,750
Total			9,11,861		3,18,67,070
Weighted Acquisition average cost of acquisition for secondary transactions					34.95

* As certified by Statutory Auditor, Chartered Accountants, by way of their certificate dated August 03, 2026.

c) Since there is an eligible transaction of our Company reported under (b) above, the price per Equity Share of our Company based on the last five primary or secondary transactions in Equity Shares (secondary transactions where the Promoters/Promoter Group entities or Shareholder(s) having the right to nominate director(s) on the Board are a party to the transaction) not older than three years prior to the date of the Red Herring Prospectus, irrespective of the size of transactions, has not been computed.

d) Weighted average cost of acquisition, Offer Price

Based on the disclosures in (b) above the weighted average cost of acquisition of Equity Shares as compared with the Price Band is set forth below:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares)	No. of times at Floor Price (i.e., ₹ 110/-) *	No. of times at Cap Price (i.e., ₹ 118/-) *
Weighted average cost of acquisition of primary issuances	NA	NA	NA
Weighted average cost of acquisition for secondary transactions	34.95	●	●
Weighted average cost of acquisition for past 5 primary issuances, as disclosed above	NA	NA	NA
Weighted average cost of acquisition for past 5 secondary transactions, as disclosed above	NA	NA	NA

*As certified by Statutory Auditor, Chartered Accountants, by way of their certificate dated August 03, 2026.

ADDITIONAL INFORMATION FOR INVESTORS

1. Details of proposed /undertaken pre-offer placements from the DRHP filing date - Our Company has not undertaken any Pre-IPO Placements from the DRHP filing date.

2. Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of our Company by promoter(s) and promoter group(s) from the DRHP filing date – None of our promoter(s) and promoter group(s) have undertaken any transaction of shares aggregating up to 1% or more of the paid-up equity share capital of our Company from the DRHP filing date.

3. Pre-Offer Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of our Company:

Sr. No.	Name of Shareholder	Pre-Issue shareholding as at the date of Advertisement		Post-Issue shareholding as at Allotment ⁽³⁾			
		Number of Equity Shares	Share Holding (in %)	At the lower end of the price band i.e. ₹ 110/-		At the upper end of the price band i.e. ₹ 118/-	
				Number of Equity Shares	Share holding (in %)	Number of Equity Shares	Share holding (in %)
Promoters							
1	Dr. Chalasani Kuldeep Kumar (Promoter Selling shareholder)	80,87,586	48.44	78,73,186	35.71%	78,73,186	35.71%
2	Dr. Chalasani Kavitha (Promoter Selling shareholder)	16,34,737	9.79	14,91,737	6.77%	14,91,737	6.77%
3	M/s Sri Ram Medicare Private Limited (Promoter Selling shareholder)	45,87,154	27.48	44,44,154	20.16%	44,44,154	20.16%
4	Ms. Chalasani Lalitakumari	-	-	-	-	-	-
5	Ms. Chalasani Durga Aashritha	-	-	-	-	-	-
Promoter Group ⁽²⁾ NA							
Top 10 Shareholders ⁽⁴⁾							
1.	Mr. Yash Hitesh Patel	8,34,756	5.00%	8,34,756	3.79	8,34,756	3.79
2.	Ms. Yashvi Hitesh Patel	7,92,831	4.75%	7,92,831	3.60	7,92,831	3.60
3.	Ms. Sumita Mishra	3,33,892	2.00%	3,33,892	1.51	3,33,892	1.51
4.	Mr. Sadineni Raghu Teja	2,14,214	1.28%	2,14,214	0.97	2,14,214	0.97
5.	Mr. Siva Rama Krishna Prasad Attluri	83,863	0.50%	83,863	0.38	83,863	0.38
6.	Ms. Karri Mani Kumari	41,925	0.25%	41,925	0.19	41,925	0.19
7.	Mr. Swapnil Sudhakar Rao Topale	41,925	0.25%	41,925	0.19	41,925	0.19
8.	Mr. Jay Ashok Shah	20,956	0.13%	20,956	0.10	20,956	0.10
9.	Ms. Priti Surya Prakash Mishra	20,956	0.13%	20,956	0.10	20,956	0.10
10.	NA	NA	NA	NA	NA	NA	NA
Total		1,66,94,795	100.00%	1,61,94,395	73.46%	1,61,94,395	73.46%

Notes:

1) Assuming full subscription in the Offer. The post-offer shareholding details as at allotment will be based on the actual subscription and the final Offer price and updated in the prospectus, subject to finalization of the basis of allotment. Also, this table assumes there is no transfer of shares by these shareholders between the date of the advertisement and allotment (if any such transfers occur prior to the date of prospectus, it will be updated in the shareholding pattern in the prospectus).

2) As on the date of the Red Herring Prospectus, we have total 12 (Twelve) shareholders, out of which 9 (Nine) are Public Shareholder.

BASIS FOR OFFER PRICE

The "Basis for Offer Price" on page 106 of the RHP has been updated with the above price band. Please refer to the website of the BRLM for the "Basis for Offer Price" updated with the above price band. You can scan the QR code given on the first page of this Advertisement for the chapter titled "Basis for Offer Price" on page 106 of the Red Herring Prospectus.

INDICATIVE TIMELINES FOR THE ISSUE	
Sequence of Activities	Listing within T+3 days (T is Offer Closing Date)
Application Submission by Investors	Electronic Applications (Online ASBA through 3-in-1 accounts) – Upto 5 pm on T Day. Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc) – Upto 4 pm on T Day. Electronic Applications (Syndicate Non-Institutional, Non-Individual Applications) – Upto 3 pm on T Day. Physical Applications (Bank ASBA) – Upto 1 pm on T Day. Physical Applications (Syndicate Non-Institutional, Non- Individual Applications of QIBs and NIIIs) – Upto 12 pm on T Day and Syndicate members shall transfer such applications to banks before 1 pm on T Day

Bid Modification	From Issue opening date up to 5 pm on T Day
Validation of bid details with depositories	From Issue opening date up to 5 pm on T Day
Reconciliation of UPI mandate transactions (Based on the guidelines issued by NPCI from time to time): Among Stock Exchanges – Sponsor Banks – NPCI and NPCI – PSPs/TPAPs** – Issuer Banks. Reporting formats of bid information, UPI analysis report and compliance timelines.	On Daily basis Merchant Bakers to submit to SEBI, sought as and when.
UPI Mandate acceptance time	T day – 5 pm
Offer Closure	T day – 4 pm for QIB and NII categories T day – 5 pm for II and other reserved categories
Third party check on UPI applications	On daily basis and to be completed before 9:30 AM on T+1 day.
Third party check on Non-UPI applications	On daily basis and to be completed before 1 pm on T+1 day.
Submission of final certificates: -For UPI from Sponsor Bank -For Bank ASBA, from all SCSBs -For syndicate ASBA	UPI ASBA – Before 9:30 pm on T Day All SCSBs for Direct ASBA – Before 07:30 pm on T Day Syndicate ASBA - Before 07:30 pm on T Day
Finalization of rejections and completion of basis	Before 6 pm on T+1 day.
Approval of basis by Stock Exchange	Before 9 pm on T+1 day.
Issuance of fund transfer instructions in separate files for debit and unblock. For Bank ASBA and Online ASBA – To all SCSBs For UPI ASBA – To Sponsor Bank	Intimation not later than 9:30 am on T+2 day. Completion before 2 pm on T+2 day for fund transfer. Completion before 4 pm on T+2 day for unblocking.
Corporate action execution for credit of shares	Initiation before 2 pm on T+2 day Completion before 6 pm on T+2 day
Filing of Listing Application with Stock Exchanges and issuance of trading notice	Before 7:30 pm on T+2 day
Publish allotment advertisement	On the website of Issuer, Merchant Banker and RTI - before 9 pm on T+2 day. In newspapers - on T+3 day but not later than T+4 day
Trading starts	T+3 day

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects of our Company, see "History and Certain Corporate Matters" on page 173 of the Red Herring Prospectus. The Memorandum of Association of our Company is a material document for inspection in relation to the Offer. For further details, see the section "Material Contracts and Documents for Inspection" on page 409 of the Red Herring Prospectus.

LIABILITY OF MEMBERS AS PER MOA: The Liability of the members of the Company is Limited.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The authorized share capital of the Company is 2,500.00 Lakhs divided into 2,50,00,000 Equity Shares of ₹ 10/- each. The issued, subscribed and paid-up share capital of the Company before the Offer is ₹ 1,66,94.48 Lakhs divided into 1,66,94,795 Equity Shares of ₹ 10/- each. For details of the Capital Structure, see "Capital Structure" on the page 82 of the Red Herring Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM:


ORIGINAL SIGNATORIES			CURRENT PROMOTERS	
Name of Promoters	Face Value (₹)	No. of Shares	Name of Promoters	Face Value (₹) No. of Shares
Raja Rao Yalamanchili	10.00	10	Dr. Chalasani Kuldeep Kumar	10.00 80,87,586
			Dr. Chalasani Kavitha	10.00 16,34,737
			M/s. Sri Ram Medicare Private Limited	10.00 45,87,154
			Ms. Chalasani Durga Aashritha	- -
Hymavathi Yalamanchali	10.00	10	Ms. Chalasani Lalitakumari	- -

LISTING: The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on the Emerge Platform of NSE ("NSE EMERGE"). Our Company has received an "In-principle" approval from the NSE for the listing of the Equity Shares pursuant to letter dated July 10, 2026. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of the Red Herring Prospectus has been submitted for registration to ROC on August 04, 2026 and Prospectus shall be filed with the RoC in accordance with Section 26(4) of the Companies Act, 2013.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"): Since the Offer is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no specific disclaimer clause of SEBI. However, investors may refer to the entire "Disclaimer Clause of SEBI" beginning on page 344 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF NSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE, nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the "Disclaimer Clause of NSE" beginning on page 345 of the Red Herring Prospectus.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of the Offeror and this Offer, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 24 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER TO THE OFFER	REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
 SMART HORIZON CAPITAL ADVISORS PRIVATE LIMITED Address: B/908, Western Edge II, Kanakia Space, Behind Metro Mall, off Western Express Highway, Magathane, Borivali East, Mumbai – 400066, Maharashtra, India. Telephone: 022-28706822 E-mail: director@shcapl.com Investors Grievance e-mail: investor@shcapl.com Contact Person: Mr. Parth Shah Website: www.shcapl.com SEBI Registration No.: INM000013183	 PURVA SHAREREGISTRY (INDIA) PRIVATE LIMITED Address: Unit No. 9, Shiv Shakti Industrial Estate, J. R. Boricha Marg, Lower Parel (East), Mumbai – 400011. Tel No: 022 - 49614132 Email: newissue@purvashare.com Website: www.purvashare.com Investor Grievance Email Id: newissue@purvashare.com Contact Person: Ms. Deepali Gaonkar SEBI Registration Number: INR000001112	 PRAMODINI MEDICARE LIMITED Mr. Rushikesh Vijay Gosavi Company Secretary & Compliance Officer Address: D. No: - 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India – 520002 Tel. No.: +91- 91 9985782727 Email: investors@pramodinidiagnostics.com; Website: www.pramodinidiagnostics.com Investors can contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-offer or post-offer related grievances, grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all offer related queries and for redressal of complaints, investors may also write to the BRLM.

Availability of Red Herring Prospectus: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein, before applying in the Offer. Full copy of the Red Herring Prospectus will be available at the website of SEBI at www.sebi.gov.in; the website of Stock Exchange at <https://www.nseindia.com/>; the website of BRLM at www.shcapl.com and website of Company at www.pramodinidiagnostics.com.

Availability of Bid-Cum-Application forms: Bid-Cum-Application forms can be obtained from our Company: Pramodini Medicare Limited, Book Running Lead Manager: Smart Horizon Capital Advisors Private Limited. Application Forms can also be obtained from the Stock Exchange and list of SCSBs available on the website of SEBI at www.sebi.gov.in and website of Stock Exchange at <https://www.nseindia.com>.

Application Supported by Blocked Amount (ASBA): All investors in this Offer have to compulsorily apply through ASBA. The investors are required to fill the ASBA form and submit the same to their banks. The SCSB will block the amount in the account as per the authority contained in ASBA form. On allotment, amount will be unblocked and account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need of refund.

For more details on the Offer process and how to apply, please refer to the details given in application forms and abridged prospectus and also please refer to the chapter "Offer Procedure" on page 369 of the Red Herring Prospectus.

BANKER TO THE OFFER: Kotak Mahindra Bank Limited
All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

For PRAMODINI MEDICARE LIMITED
Sd/-
Chalasani Kuldeep Kumar
Designation: Chairman & Managing Director
DIN: 03142837

Date: August 04, 2026
Place: Andhra Pradesh

Pramodini Medicare Limited is proposing, subject to market conditions and other considerations, public issue of its Equity Shares and has filed the Red Herring Prospectus with the Registrar of Companies, Andhra Pradesh on August 04, 2026. The Red Herring Prospectus is available on the website of the Book Running Lead Manager at www.shcapl.com, the website of the NSE i.e., <https://www.nseindia.com>, and website of our Company at www.pramodinidiagnostics.com.

Investor should note that investment in equity shares involves a high degree of risk. For details, investors should refer to and rely on the Red Herring Prospectus, including the section titled "Risk Factors" of the Red Herring Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the U.S. Securities Act ("the Securities Act") or any state securities laws in United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulations under the securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933.

CAMAC COMMERCIAL COMPANY LIMITED

(CIN: L70109DL1980PLC169318)

Regd Office: 2nd Floor, Property No. 22-A, Asaf Ali Road, New Delhi – 110002

Mobile No.: 7303495374; Email: camaccommercial@gmail.com

Website: www.camaccommercial.com

PUBLIC NOTICE

Subject: Special Window for Re-lodgement of Transfer Requests for Physical Shares

Pursuant to SEBI Circular No. SEBI/HO/38/13/11(2)/2026-MIRSD-POD/13/750/2026 dated January 30, 2026 and in continuation of public notice given by the company dated February 05, 2026, April 16, 2026, and June 02, 2026 please note that the Company has offered another Special Window for shareholders to submit re-lodgement requests for the transfer of physical shares.

This Special Window has been opened from February 05, 2026 to February 04, 2027, and is specifically applicable to cases where the original transfer requests were lodged prior to April 01, 2019, and were returned corrected due to deficiencies in documentation, process, or any other reason.

Kindly note that during this window, shares re-lodged for transfer will be processed only in dematerialized (demat) form, in accordance with the above said circular. The circular is available on the website of the Company i.e., www.camaccommercial.com.

Eligible shareholders may submit their transfer requests along with the requisite documents to the Company or its Registrar and Share Transfer Agent (RTA) at the earliest within the stipulated period.

Ms. Manisha Saxena
(Company Secretary & Compliance Officer)
Camac Commercial Company Limited
Address: 2nd Floor, Property No. 22-A, Asaf Ali Road, New Delhi – 110002
Telephone no.: +91-7303495374
Email: camaccommercial@gmail.com

M/s. Niche Technologies Private Limited
(Registrar and Share Transfer Agent)
Address: 3A, Aukland Place, 7th Floor, Room No. 7A & 7B, Kolkata – 700017
Telephone no.: (033) 2280-6616 / 6617;
Email: nichetechpl@nichetechpl.com

For Camac Commercial Company Limited
Sd/-
Manisha Saxena
Company Secretary & Compliance Officer

Date: August 04, 2026



CHEMCRUX ENTERPRISES LIMITED

(CIN: L01110GJ1996PLC029329)

Regd. Off.: 330, TRIVIA Complex, Natubhai Circle, Racecourse, Vadodara – 390007

Email: girishshah@chemcrux.com Ph.: 0265-2984803/2988903 Website: www.chemcrux.com

UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR

THE QUARTER ENDED 30TH JUNE 2026

(1) The financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04th August 2026. The figures for the quarter ended 30th June 2026 have been subjected to limited review by the statutory auditors.

(2) The figures of the corresponding previous period have been regrouped and reclassified wherever considered necessary to confirm to the figures represented in the current period.

(3) The Quarterly Financial Results have been posted on the website of stock exchange BSE Limited at www.bseindia.com and on Company's website at www.chemcrux.com. The same can also be accessed by scanning QR Code given below:



By the order of the Board

For CHEMCRUX ENTERPRISES LIMITED

Sd/-

Mr. Girishkumar Shah (Whole Time Director)

(DIN:00469291)

Date: 4th August 2026

Place: Vadodara

epaper.financialexpress.com





ESTER INDUSTRIES LIMITED

CIN - L24111UR1985PLC015063

Regd. Off: Sohan Nagar, P.O. Charubeta, Khatima - 262308

Distt. Udham Singh Nagar, Uttarakhand

Website: www.esterindustries.com; Email: investor@ester.in

Phone No.: (05943) 250153-57; Fax No.: (05943) 250158

NOTICE TO SHAREHOLDERS

SPECIAL WINDOW FOR TRANSFER AND DEMATERIALIZATION OF PHYSICAL SECURITIES

In terms of SEBI Circular No.: HO/38/13/11(2)/2026-MIRSD-POD/13/750/2026 dated 30th January 2026 on the above referred subject matter, please note that Special Window has been opened for a period of one year from 5th February 2026 to 4th February 2027, allowing shareholders to lodge, re-lodge transfer and dematerialisation request of physical securities which were sold / purchased prior to 1st April 2019, but were not lodged with the Company/RTA or rejected/returned/not attended to due to deficiency in the documents/process or otherwise.

Shareholders are informed that the request(s) which are accompanied by original certificate(s) along with transfer deeds and relevant supporting documents will only be considered under this special window. The securities so transferred shall be mandatorily credited to the transferee only in demat mode and shall be under lock-in for a period of one year from the date of registration of transfer. Such securities shall not be transferred/lien-marked/pledged during the said lock-in period.

Eligible shareholders who wish to avail this opportunity are advised to contact the Company's Registrar and Transfer Agent (RTA) MAS Services Limited at their address T-34, IInd Floor, Okhla Industrial Area, Phase-II, New Delhi-110020 or at their email address at investor@masserv.com or send an email to the Company at investor@ester.in at the earliest so as to enable the Company / RTA to complete the transfer / demat process on or before the deadline of 4th February 2027.

For Ester Industries Limited
Sd/-
Poornima Gupta
Company Secretary and Compliance Officer

Date: 4th August 2026
Place: Gurgaon

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



(Please scan this QR code to view the RHP)

PRAMODINI MEDICARE LIMITED

CIN: U85110AP2000PLC035231

Our Company was originally incorporated on September 12, 2000 under the name “Pramodini Medicare Private Limited” under the provisions of the Companies Act, 1956 with the Registrar of Companies, Andhra Pradesh, Hyderabad. Thereafter, the status of our Company was changed to public limited Company and the name of our Company was changed to “Pramodini Medicare Limited” vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on October 30, 2025. The fresh certificate of incorporation consequent to conversion was issued on November 12, 2025 by the Centralised Processing Centre. The Corporate Identification Number of our Company is U85110AP2000PLC035231. For further details on Incorporation and Registered Office of our Company, see “History and Certain Corporate Matters” beginning on page 173 of the Red Herring Prospectus.

Registered Office: D. No: - 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India - 520002

Tel No: +91- 9985782727 | E-mail: investors@pramodinidiagnostics.com | Website: www.pramodinidiagnostics.com

Contact Person: Mr. Rushikesh Vijay Gosavi, Company Secretary and Compliance Officer

THE PROMOTERS OF OUR COMPANY ARE DR. CHALASANI KULDEEP KUMAR, DR. CHALASANI KAVITHA, MS. CHALASANI DURGA AASHRITHA, MS. CHALASANI LALITAKUMARI AND M/S. SRI RAM MEDICARE PRIVATE LIMITED.

“THE OFFER IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE (NSE EMERGE).”

THE OFFER

INITIAL PUBLIC OFFER OF UP TO 58,51,200* EQUITY SHARES OF FACE VALUE OF ₹10/- EACH (THE “EQUITY SHARES”) OF PRAMODINI MEDICARE LIMITED (“OUR COMPANY” OR “PRAMODINI” OR “THE OFFEROR”) AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [●] LAKHS COMPRISING OF FRESH OFFER OF UP TO 53,50,800 EQUITY SHARES AGGREGATING TO ₹ [●] LAKHS (“FRESH OFFER”) AND AN OFFER FOR SALE OF UP TO 5,00,400 EQUITY SHARES BY DR. CHALASANI KULDEEP KUMAR, DR. CHALASANI KAVITHA AND M/S. SRI RAM MEDICARE PRIVATE LIMITED (“PROMOTER SELLING SHAREHOLDERS”) AGGREGATING TO ₹ [●] LAKHS (“OFFER FOR SALE”) (“PUBLIC OFFER”). THE OFFER INCLUDES A RESERVATION OF UP TO 3,36,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH, AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKERS TO THE OFFER (THE “MARKET MAKER RESERVATION PORTION”). THE PUBLIC OFFER LESS MARKET MAKER RESERVATION PORTION I.E. NET OFFER OF UP TO 55,15,200 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH, AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET OFFER”. THE PUBLIC OFFER AND NET OFFER WILL CONSTITUTE 26.54% AND 25.02% RESPECTIVELY OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

*Subject to finalisation of basis of allotment.

DETAILS OF OFFER FOR SALE, PROMOTER SELLING SHAREHOLDERS AND THEIR WEIGHTED AVERAGE COST OF ACQUISITION:

Name	Type	No. Of Shares Offered/ Amount in ₹	WACA per Equity Share in (₹*)
Dr. Chalasani Kuldeep Kumar	Promoter Selling Shareholder	Up to 2,14,400 Equity Shares	6.99
Dr. Chalasani Kavitha	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares	6.23
M/s. Sri Ram Medicare Private Limited	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares	4.25

*As certified by Statutory Auditor of our Company, by way of their certificate dated August 03, 2026.

PRICE BAND: ₹ 110/- to ₹ 118/- PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH

THE FLOOR PRICE IS 11.00 TIMES THE FACE VALUE OF THE EQUITY SHARES AND
CAP PRICE IS 11.80 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FY 2025-26 AT THE FLOOR PRICE IS 10.57 TIMES AND AT THE CAP PRICE IS 11.34 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF 1,200 EQUITY SHARES AND IN MULTIPLES OF 1,200 EQUITY SHARES THEREAFTER.

ISSUE PROGRAM

ANCHOR BID OPENS ON: TUESDAY, AUGUST 11, 2026
OPENS ON: WEDNESDAY, AUGUST 12, 2026
CLOSES ON: FRIDAY, AUGUST 14, 2026

BRIEF DESCRIPTION OF THE BUSINESS OF THE OFFEROR

Our Company is a diagnostic service provider in India. We provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. The services offered at each location vary based on the scope agreed under the respective MOUs. We provide healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions Our diagnostic services include a comprehensive range of offerings: (i) “Radiology” which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) “Clinical Laboratory” which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) “Nuclear Medicine” which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy. For more details, please refer chapter titled “Our Business” beginning on page 135 of the Red Herring Prospectus.

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON EMERGE PLATFORM OF NSE. FOR THE PURPOSE OF THE OFFER, THE DESIGNATED STOCK EXCHANGE SHALL BE NSE.

ALLOCATION OF THE ISSUE

QIB PORTION	NOT MORE THAN 50.00% OF THE NET OFFER
INDIVIDUAL INVESTOR PORTION	NOT LESS THAN 35.00% OF THE NET OFFER
NON-INSTITUTIONAL PORTION	NOT LESS THAN 15.00% OF THE NET OFFER
MARKET MAKER PORTION	UPTO 3,36,000 EQUITY SHARES OR 5.74% OF THE OFFER

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RED HERRING PROSPECTUS AND THE TERMS OF THE OFFER, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE OFFER AVAILABLE IN ANY MANNER.

The price band is justified based on the qualitative factors, quantitative factors and KPIs disclosed in the chapter title “Basis for Offer Price” beginning on page 106 of the Red Herring Prospectus.

RISKS TO INVESTORS

1. Risk to Investors: Summary description of key risk factors based on materiality, for details refer to Section titled “ Risk Factors” on page 24 of the Red Herring Prospectus:

The below mentioned risks are top 10 risk factors as per the Red Herring Prospectus:

- A significant portion of our revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect our business, financial condition and results of operations
- Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects
- We derive substantial portion of our revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on our business, results of operations and financial condition
- We are majorly dependent on certain key customers cum patients for a substantial portion of our revenues. Loss of relationship with any of these customers cum patients may have a material adverse effect on our profitability and results of operations
- We derive a significant portion of our revenue from government authorities (B2G). Any reduction in revenue from them or delays in payments by government authorities, may adversely affect our business, financial condition and results of operations
- Failure to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations
- We rely on our information technology systems in providing our diagnostic services and managing our operations, and any disruption to such systems or networks could adversely affect our business operations, reputation and financial performance
- Any inadequacy in packaging, collection of, or failure or delay in the delivery of, specimens to our diagnostic centres could compromise or destroy the integrity of such specimens, which could adversely affect our business, results of operations and financial condition
- Our Company is not having any exact comparable Indian peer which have similar business to our Company
- We are required to furnish bank guarantees as part of our business under Strategic Partnership with PSU Govt of India. Our inability to arrange such guarantees or the invocation of such guarantees may adversely affect our cash flows and financial condition.

2. Details of suitable ratios of our Company and our peer group for the latest full financial year:

Name of Company	CMP (₹)	Face Value (₹)	Basic & Diluted EPS (₹)	P / E Ratio (times)	RoNW (%)	NAV per Share (₹)
Pramodini Medicare Limited.	[●]	10	10.41	[●]	32.69%	31.84
Peer Group						
Invicta Diagnostic Limited	66.75	10	4.90	13.62	9.76%	39.71
Krsnaa Diagnostics Limited	524.05	5	31.30	16.74	10.35%	302.23
Star Imaging & Path Labs Limited	87.00	10	11.05	7.87	16.58%	66.65

Source: www.nseindia.com and www.bseindia.com

Notes:

- The figures for our company are based on Restated Consolidated Financial Statements for the year ended March 31, 2026.
- P/E Ratio has been computed based on their respective closing market price on July 30, 2026, as divided by the Basic EPS as on March 31, 2026.
- Restated Profit for the year attributable to equity shareholders divided by Net Worth of our Company.
- Net asset value per equity share is calculated as net worth as of the end of relevant year divided by the weighted average number of equities shares outstanding at the end of the year.
- Price Earning (P/E) Ratio in relation to the Offer Price of [●] per share.
- The Price Band determined by our Company and the Promoter Selling Shareholders in consultation with the Book Running Lead Manager is justified by our Company in consultation with the Book Running Lead Manager on the basis of the above parameters.
- The peer group companies are not exactly comparable in all aspects of business and services that our Company provides.

3. Weighted Average Return on Net worth for the last 3 financial years (RoNW)
As per Restated Financial Statements:

Particulars	RoNW (%)	Weights
March 31, 2026	32.69%	3

(Continued next page...)

epaper.jansatta.com

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



(Please scan this QR code to view the RHP)

PRAMODINI MEDICARE LIMITED

CIN: U85110AP2000PLC035231

Our Company was originally incorporated on September 12, 2000 under the name “*Pramodini Medicare Private Limited*” under the provisions of the Companies Act, 1956 with the Registrar of Companies, Andhra Pradesh, Hyderabad. Thereafter, the status of our Company was changed to public limited Company and the name of our Company was changed to “*Pramodini Medicare Limited*” vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on October 30, 2025. The fresh certificate of incorporation consequent to conversion was issued on November 12, 2025 by the Centralised Processing Centre. The Corporate Identification Number of our Company is U85110AP2000PLC035231. For further details on Incorporation and Registered Office of our Company, see “*History and Certain Corporate Matters*” beginning on page 173 of the Red Herring Prospectus.

Registered Office: D. No: - 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India - 520002
Tel No: +91- 9985782727 | **E-mail:** investors@pramodinidiagnostics.com | **Website:** www.pramodinidiagnostics.com
Contact Person: Mr. Rushikesh Vijay Gosavi, Company Secretary and Compliance Officer

THE PROMOTERS OF OUR COMPANY ARE DR. CHALASANI KULDEEP KUMAR, DR. CHALASANI KAVITHA, MS. CHALASANI DURGA AASHRITHA, MS. CHALASANI LALITAKUMARI AND M/S. SRI RAM MEDICARE PRIVATE LIMITED.

“THE OFFER IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE (NSE EMERGE).”

THE OFFER

INITIAL PUBLIC OFFER OF UP TO 58,51,200* EQUITY SHARES OF FACE VALUE OF ₹10/- EACH (THE “EQUITY SHARES”) OF PRAMODINI MEDICARE LIMITED (“OUR COMPANY” OR “PRAMODINI” OR “THE OFFEROR”) AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [●] LAKHS COMPRISING OF FRESH OFFER OF UP TO 53,50,800 EQUITY SHARES AGGREGATING TO ₹ [●] LAKHS (“FRESH OFFER”) AND AN OFFER FOR SALE OF UP TO 5,00,400 EQUITY SHARES BY DR. CHALASANI KULDEEP KUMAR, DR. CHALASANI KAVITHA AND M/S. SRI RAM MEDICARE PRIVATE LIMITED (“PROMOTER SELLING SHAREHOLDERS”) AGGREGATING TO ₹ [●] LAKHS (“OFFER FOR SALE”) (“PUBLIC OFFER”). THE OFFER INCLUDES A RESERVATION OF UP TO 3,36,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH, AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKERS TO THE OFFER (THE “MARKET MAKER RESERVATION PORTION”). THE PUBLIC OFFER LESS MARKET MAKER RESERVATION PORTION I.E. NET OFFER OF UP TO 55,15,200 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH, AT AN OFFER PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET OFFER”. THE PUBLIC OFFER AND NET OFFER WILL CONSTITUTE 26.54% AND 25.02% RESPECTIVELY OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

*Subject to finalisation of basis of allotment.

DETAILS OF OFFER FOR SALE, PROMOTER SELLING SHAREHOLDERS AND THEIR WEIGHTED AVERAGE COST OF ACQUISITION:

Name	Type	No. Of Shares Offered/ Amount in ₹	WACA per Equity Share in (₹*)
Dr. Chalasani Kuldeep Kumar	Promoter Selling Shareholder	Up to 2,14,400 Equity Shares	6.99
Dr. Chalasani Kavitha	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares	6.23
M/s. Sri Ram Medicare Private Limited	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares	4.25

*As certified by Statutory Auditor of our Company, by way of their certificate dated August 03, 2026.

PRICE BAND: ₹ 110/- to ₹ 118/- PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH

THE FLOOR PRICE IS 11.00 TIMES THE FACE VALUE OF THE EQUITY SHARES AND
CAP PRICE IS 11.80 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FY 2025-26 AT THE FLOOR PRICE IS 10.57 TIMES AND AT THE CAP PRICE IS 11.34 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF 1,200 EQUITY SHARES AND IN MULTIPLES OF 1,200 EQUITY SHARES THEREAFTER.

ISSUE PROGRAM

ANCHOR BID OPENS ON: TUESDAY, AUGUST 11, 2026
OPENS ON: WEDNESDAY, AUGUST 12, 2026
CLOSES ON: FRIDAY, AUGUST 14, 2026

BRIEF DESCRIPTION OF THE BUSINESS OF THE OFFEROR

Our Company is a diagnostic service provider in India. We provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. The services offered at each location vary based on the scope agreed under the respective MOUs. We provide healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions Our diagnostic services include a comprehensive range of offerings: (i) “Radiology” which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) “Clinical Laboratory” which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) “Nuclear Medicine” which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy. For more details, please refer chapter titled “Our Business” beginning on page 135 of the Red Herring Prospectus.

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON EMERGE PLATFORM OF NSE. FOR THE PURPOSE OF THE OFFER, THE DESIGNATED STOCK EXCHANGE SHALL BE NSE.

ALLOCATION OF THE ISSUE

QIB PORTION	NOT MORE THAN 50.00% OF THE NET OFFER
INDIVIDUAL INVESTOR PORTION	NOT LESS THAN 35.00% OF THE NET OFFER
NON-INSTITUTIONAL PORTION	NOT LESS THAN 15.00% OF THE NET OFFER
MARKET MAKER PORTION	UPTO 3,36,000 EQUITY SHARES OR 5.74% OF THE OFFER

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RED HERRING PROSPECTUS AND THE TERMS OF THE OFFER, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE OFFER AVAILABLE IN ANY MANNER.

The price band is justified based on the qualitative factors, quantitative factors and KPIs disclosed in the chapter title “*Basis for Offer Price*” beginning on page 106 of the Red Herring Prospectus.

RISKS TO INVESTORS

1. Risk to Investors: Summary description of key risk factors based on materiality, for details refer to Section titled “Risk Factors” on page 24 of the Red Herring Prospectus:

The below mentioned risks are top 10 risk factors as per the Red Herring Prospectus:

- A significant portion of our revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect our business, financial condition and results of operations
- Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects
- We derive substantial portion of our revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on our business, results of operations and financial condition
- We are majorly dependent on certain key customers cum patients for a substantial portion of our revenues. Loss of relationship with any of these customers cum patients may have a material adverse effect on our profitability and results of operations
- We derive a significant portion of our revenue from government authorities (B2G). Any reduction in revenue from them or delays in payments by government authorities, may adversely affect our business, financial condition and results of operations
- Failure to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations
- We rely on our information technology systems in providing our diagnostic services and managing our operations, and any disruption to such systems or networks could adversely affect our business operations, reputation and financial performance
- Any inadequacy in packaging, collection of, or failure or delay in the delivery of, specimens to our diagnostic centres could compromise or destroy the integrity of such specimens, which could adversely affect our business, results of operations and financial condition
- Our Company is not having any exact comparable Indian peer which have similar business to our Company
- We are required to furnish bank guarantees as part of our business under Strategic Partnership with PSU Govt of India. Our inability to arrange such guarantees or the invocation of such guarantees may adversely affect our cash flows and financial condition.

2. Details of suitable ratios of our Company and our peer group for the latest full financial year:

Name of Company	CMP (₹)	Face Value (₹)	Basic & Diluted EPS (₹)	P / E Ratio (times)	RoNW (%)	NAV per Share (₹)
Pramodini Medicare Limited	[●]	10	10.41	[●]	32.69%	31.84
Peer Group						
Invicta Diagnostic Limited	66.75	10	4.90	13.62	9.76%	39.71
Krsnaa Diagnostics Limited	524.05	5	31.30	16.74	10.35%	302.23
Star Imaging & Path Labs Limited	87.00	10	11.05	7.87	16.58%	66.65

Source: www.nseindia.com and www.bseindia.com

Notes:

- The figures for our company are based on Restated Consolidated Financial Statements for the year ended March 31, 2026.
- P/E Ratio has been computed based on their respective closing market price on July 30, 2026, as divided by the Basic EPS as on March 31, 2026.
- Restated Profit for the year attributable to equity shareholders divided by Net Worth of our Company.
- Net asset value per equity share is calculated as net worth as of the end of relevant year divided by the weighted average number of equities shares outstanding at the end of the year.
- Price Earning (P/E) Ratio in relation to the Offer Price of [●] per share.
- The Price Band determined by our Company and the Promoter Selling Shareholders in consultation with the Book Running Lead Manager is justified by our Company in consultation with the Book Running Lead Manager on the basis of the above parameters.
- The peer group companies are not exactly comparable in all aspects of business and services that our Company provides.

3. Weighted Average Return on Net worth for the last 3 financial years (RoNW)
As per Restated Financial Statements:

Particulars	RoNW (%)	Weights
March 31, 2026	32.69%	3

(Continued next page...)



కెన్ ఫిన్ హోమ్స్ లిమిటెడ్
బ్రాంచ్- బెర్హంపూర్, నెల్లూ పార్క్ దగ్గర, హిరపాటా
రెజిస్ట్రేషన్ నో.బి, బెర్హంపూర్, జిల్లా: గంజాం, ఒడిశా-760005

అనుబంధం- IV-A [నియమం 8 (6) నిబంధన చూడండి].
స్థిరాస్తుల అమ్మకానికి అనుకూల నోటీసు

సెక్యూరిటీజెషన్ అండ్ రిజిస్ట్రేషన్ ఆఫ్ ప్రాపర్టీస్ అండ్ ఎస్టేట్స్ అండ్ సెక్యూరిటీ ఇంట్రస్ట్రీ చట్టం, 2002 మరియు రూల్ 8 (6) యొక్క నిబంధనలో కలిపి పదనీబంధు సెక్యూరిటీ ఇంట్రస్ట్రీ (ఎస్టేట్స్) నియమాలు, 2002 క్రింద స్థిరాస్తుల అమ్మకానికి సంబంధించిన ఇ-వెలం అనుకూల నోటీసు.

ఇందుమూలముగా సాధారణ ప్రజలకు ముఖ్యంగా రూఢిగ్రాత(లు) మరియు హామీదారు(లు)లకు తెలియజేయునది ఏమనగా కేవలంకే సాహు, కృష్ణ సాహ మరియు కామిన సాహ (రుఢిగ్రాతలు) వారి నుండి కెన్ ఫిన్ హోమ్స్ లిమిటెడ్ కు చెల్లించవలసిన రూ.18,97,822/- (రూపాయలు పన్నెండు లక్షల తొంభై ఏడు వేల ఏనిమిది వందల ఇరవై రెండు మాత్రమే) 27/07/2026 నాటికి మొత్తంగా దానిపై మున్పుండు పశ్చి మరియు ఇతర ఛార్జీలతో సహా పన్నులు చేయవలసి కెన్ ఫిన్ హోమ్స్ లిమిటెడ్, బెర్హంపూర్ బ్రాంచ్ యొక్క అధికార అధికారి నిర్మాణాత్మక/భౌతిక స్వాధీనం చేసుకున్న సెక్యూరిటీ క్రెడిటార్ కు తనఖా సెట్టింగ్/ఛార్జ్ చేయబడిన క్రింద వివరించిన స్థిరాస్తిని “ఎక్స్ డి ఎలా ఉందో అక్కడ అలా”, “ఉన్నది ఉన్నట్లుగా” మరియు “ ఏదయినా ఉందో అది” ప్రాతిపదికన 09/08/2026వ తేదీన ఇ-వెలం ద్వారా అమ్మడం జరుగుతుంది. రిజర్వ్ ధర రూ. 20,00,000/- (రూపాయలు ఇరవై లక్షలు మాత్రమే) మరియు ఎన్నికైన డిపాజిట్ రూ. 2,00,000/- (రూపాయలు రెండు లక్షలు మాత్రమే).

తనఖా ఉంచబడిన అస్తి యొక్క వివరాలు

భా. సం. 767/10521, షెడ్. సం. 261/8814, శ్రీ కృష్ణ విహార్, పి.ఓ.: బెర్హంపూర్, పి.ఎం.: బా ఖాడో, జిల్లా: గంజాం, ఒడిశా-760001

అస్తి పీడ దుబారాలు - ఏమి లేవు

అమ్మకానికి సంబంధించిన వివరణాత్మక నిబంధనలు మరియు షరతులు కెన్ ఫిన్ హోమ్స్ లిమిటెడ్ అధికారిక వెబ్సైట్ (<https://www.canfinhomes.com/SearchAuction.aspx>) లో ఉంచబడబడ్డాయి.

ఇ-వెలం పోర్టల్ దానికి లింక్: www.bankeauctionwizard.com

తేది: 05.08.2026
ప్రదేశం: బెర్హంపూర్

సం/-
అధికృత అధికారి,
కెన్ ఫిన్ హోమ్స్ లి.

“అభివృద్ధి అడుగులు - సంక్షేమం వెలుగులు” కార్యక్రమంలో జనసేన ఇంటింటి ప్రచారం

కిషోర్ గునుకుల, శ్రీమతి విజయలక్ష్మి-జనసేన

నెల్లూరు జిల్లా ప్రతినిధి, ఆగస్టు 4, (సాక్షిం)

నెల్లూరు నగరం 16వ డివిజన్ లో “అభివృద్ధి అడుగులు - సంక్షేమం వెలుగులు” కార్యక్రమంలో భాగంగా జనసేన పార్టీ నాయకులు కిషోర్ గునుకుల ఇంటింటికి వెళ్లి కూటమి ప్రభుత్వం గత రెండేళ్లుగా చేపట్టిన అభివృద్ధి, సంక్షేమ కార్యక్రమాలను ప్రజలకు వివరిస్తూ, రానున్న మున్సిపల్ కార్పొరేషన్ ఎన్నికల్లో కూటమి అభ్యర్థులకు మద్దతు ఇవ్వాలని కోరారు. ఈ సందర్భంగా జనసేన పార్టీ జిల్లా నాయకులు కిషోర్ గునుకుల, ఏఎస్సీ డైరెక్టర్ శ్రీమతి విజయలక్ష్మి, వీరమహేశ్వర్ కలిసి స్థానిక ప్రముఖులను కలుసుకుని అభివృద్ధి కరవత్రాలను పంపిణీ చేశారు. కూటమి ప్రభుత్వం ఏర్పడిన అనంతరం నెల్లూరు నగరంలో, ముఖ్యంగా 16వ డివిజన్ లో చేపట్టిన అభివృద్ధి కార్యక్రమాల, ప్రజా సంక్షేమ చర్యలను వివరించారు. అలాగే ప్రజా సమస్యల పరిష్కారం కోసం నిరంతరం ప్రజల తరపున పోరాడుతున్న కిషోర్ గునుకుల చేస్తున్న సేవలను ప్రజలకు వివరించారు. రాష్ట్రవ్యాప్తంగా ప్రజా సంక్షేమం, పౌరదర్శక పాలన కోసం ఉప ముఖ్యమంత్రి, జనసేన పార్టీ అధ్యక్షులు శ్రీ పవన్ కళ్యాణ్ గారు అందిస్తున్న సేవలు, ముఖ్యమంత్రి శ్రీ నారా చంద్రబాబు నాయుడు గారి దూరదృష్టి పాలన, మున్సిపల్ శాఖ మంత్రి, నెల్లూరు సీట్ ఎమ్మెల్యే డాక్టర్ పొంగూరు నారాయణ గారి నాయకత్వంలో నెల్లూరు నగరంలో జరుగుతున్న అభివృద్ధి కార్యక్రమాలను ప్రజలకు తెలియజేశారు.

ఈ కార్యక్రమంలో 16వ డివిజన్ ప్రముఖులు కొట్టి రామ్మూర్తి, బీజేపీ నాయకులు ముక్కు రాధాకృష్ణ గౌడ్, మధు, శ్రీధర్ తదితరుల కుటుంబసభ్యులను కలిసి డివిజన్ లో చేపట్టిన అభివృద్ధి పనులను వివరించే కరవత్రాలను ప్రజలకు పంపిణీ చేశారు. ఈ కార్యక్రమంలో జనసేన పార్టీ నాయకులు కిషోర్ గునుకుల, శ్రీమతి విజయలక్ష్మి, వెంగయ్య తదితరులు పాల్గొన్నారు. ఈ డ్రెస్ నోట్స్ పత్రికల్లో ప్రచురించేందుకు ఆకర్షణీయమైన శీర్షికగా “అభివృద్ధి అడుగులు - సంక్షేమం వెలుగులు: 16వ డివిజన్ లో ఇంటింటి ప్రచారానికి విశేష స్పందన” అనేది బాగా సహజమింది.



కెన్ ఫిన్ హోమ్స్ లిమిటెడ్
బ్రాంచ్- బెర్హంపూర్, నెల్లూ పార్క్ దగ్గర, హిరపాటా
రెజిస్ట్రేషన్ నో.బి, బెర్హంపూర్, జిల్లా: గంజాం, ఒడిశా-760005

అనుబంధం- IV-A [నియమం 8 (6) నిబంధన చూడండి].
స్థిరాస్తుల అమ్మకానికి అనుకూల నోటీసు

సెక్యూరిటీజెషన్ అండ్ రిజిస్ట్రేషన్ ఆఫ్ ప్రాపర్టీస్ అండ్ ఎస్టేట్స్ అండ్ సెక్యూరిటీ ఇంట్రస్ట్రీ చట్టం, 2002 మరియు రూల్ 8 (6) యొక్క నిబంధనలో కలిపి పదనీబంధు సెక్యూరిటీ ఇంట్రస్ట్రీ (ఎస్టేట్స్) నియమాలు, 2002 క్రింద స్థిరాస్తుల అమ్మకానికి సంబంధించిన ఇ-వెలం అనుకూల నోటీసు.

ఇందుమూలముగా సాధారణ ప్రజలకు ముఖ్యంగా రూఢిగ్రాత(లు) మరియు హామీదారు(లు)లకు తెలియజేయునది ఏమనగా శ్రీ కృష్ణ విహార్, శ్రీమతి గుమ్మడి శ్రీవాలు (రుఢిగ్రాతలు) మరియు కెలి డిల్లీ రావు (గ్యారంటీర్) వారి నుండి కెన్ ఫిన్ హోమ్స్ లిమిటెడ్ కు చెల్లించవలసిన రూ.11,17,055/- (రూపాయలు పదిహేడు లక్షల పదిహేడు వేల యాభై ఐదు మాత్రమే) 27/07/2026 నాటికి మొత్తంగా దానిపై మున్పుండు పశ్చి మరియు ఇతర ఛార్జీలతో సహా పన్నులు చేయవలసి కెన్ ఫిన్ హోమ్స్ లిమిటెడ్, బెర్హంపూర్ బ్రాంచ్ యొక్క అధికార అధికారి నిర్మాణాత్మక/భౌతిక స్వాధీనం చేసుకున్న సెక్యూరిటీ క్రెడిటార్ కు తనఖా సెట్టింగ్/ఛార్జ్ చేయబడిన క్రింద వివరించిన స్థిరాస్తిని “ఎక్స్ డి ఎలా ఉందో అక్కడ అలా”, “ఉన్నది ఉన్నట్లుగా” మరియు “ ఏదయినా ఉందో అది” ప్రాతిపదికన 19/08/2026వ తేదీన ఇ-వెలం ద్వారా అమ్మడం జరుగుతుంది. రిజర్వ్ ధర రూ. 11,50,000/- (రూపాయలు పదిహేండు లక్షల యాభై వేలు మాత్రమే) మరియు ఎన్నికైన డిపాజిట్ రూ. 1,15,000/- (రూపాయలు ఒక లక్షా పదిహేండు వేలు మాత్రమే).

తనఖా ఉంచబడిన అస్తి యొక్క వివరాలు

భా. సం: 7-3, సబ్స్ సం. 50/4, మునిభద్ర, పి.ఓ.: మండవల్లి, పి.ఎం.: బెర్హంపూర్, జిల్లా: శ్రీరామేశ్వరం, ఆంధ్రప్రదేశ్, 532312.

అస్తి పీడ దుబారాలు - ఏమి లేవు

అమ్మకానికి సంబంధించిన వివరణాత్మక నిబంధనలు మరియు షరతులు కెన్ ఫిన్ హోమ్స్ లిమిటెడ్ అధికారిక వెబ్సైట్ (<https://www.canfinhomes.com/SearchAuction.aspx>) లో ఉంచబడబడ్డాయి.

ఇ-వెలం పోర్టల్ దానికి లింక్: www.bankeauctionwizard.com

తేది: 05.08.2026
ప్రదేశం: బెర్హంపూర్

సం/-
అధికృత అధికారి,
కెన్ ఫిన్ హోమ్స్ లి.

(Continued from previous page...)

March 31, 2025		30.83%		2
March 31, 2024		28.00%		1
Weighted Average		31.29%		

Note: Return on Net Worth (%) = Profit for the period/ year / Net Worth at the end of the period/year.

4. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI as applicable:

a) The price per share of our Company based on the primary/ new issue of shares (equity / convertible securities), excluding shares issued under ESOP/ ESOS and issuance of bonus shares

There has been no issuance of Equity Shares (excluding shares issued under ESOP/ESOS and issuance of bonus shares) during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-offer capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days.

b) The price per share of our Company based on the secondary sale / acquisition of shares (equity shares)

Except as mentioned below, there have been no secondary sale / acquisitions of Equity Shares, where the promoters, members of the promoter group, selling shareholder or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-offer share capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

Date of Transaction	Name of Transferor	Name of Transferee	Number of Equity Shares Acquired/sold	Acquisition/ Transfer Price (₹)	Total consideration (₹)
March 10, 2025	Dr. Chalasani Kuldeep Kumar	Mr. Yash Hitesh Patel	6,42,120	31/-	1,99,05,720
March 17, 2025		Ms. Sumita Mishra	2,56,840	31/-	79,62,040
The existing equity shares of face value of ₹1/- each were consolidated into equity shares of face value of ₹10/- each vide shareholders' resolution dated March 30, 2025.					
April 02, 2025	Dr. Chalasani Kuldeep Kumar	Mr. Siva Rama Krishna Prasad Atluri	6,451	310/-	19,99,810
April 02, 2025		Ms. Karri Mani Kumari	3,225	310/-	9,99,750
April 03, 2025		Mr. Swapnil Sudhakarrao Topale	3,225	310/-	9,99,750
Total			9,11,861		3,18,67,070

Weighted Acquisition average cost of acquisition for secondary transactions

34.95

* As certified by Statutory Auditor, Chartered Accountants, by way of their certificate dated August 03, 2026.

c) Since there is an eligible transaction of our Company reported under (b) above, the price per Equity Share of our Company based on the last five primary or secondary transactions in Equity Shares (secondary transactions where the Promoters/Promoter Group entities or Shareholder(s) having the right to nominate director(s) on the Board are a party to the transaction) not older than three years prior to the date of the Red Herring Prospectus, irrespective of the size of transactions, has not been computed.

d) Weighted average cost of acquisition, Offer Price

Based on the disclosures in (b) above the weighted average cost of acquisition of Equity Shares as compared with the Price Band is set forth below:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares)	No. of times at Floor Price (i.e., ₹ 110/-) *	No. of times at Cap Price (i.e., ₹ 118/-) *
Weighted average cost of acquisition of primary issuances	NA		NA
Weighted average cost of acquisition for secondary transactions	34.95	●	●
Weighted average cost of acquisition for past 5 primary issuances, as disclosed above	NA	NA	NA
Weighted average cost of acquisition for past 5 secondary transactions, as disclosed above	NA	NA	NA

*As certified by Statutory Auditor, Chartered Accountants, by way of their certificate dated August 03, 2026.

ADDITIONAL INFORMATION FOR INVESTORS

1. Details of proposed /undertaken pre-offer placements from the DRHP filing date - Our Company has not undertaken any Pre-IPO Placements from the DRHP filing date.

2. Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of our Company by promoter(s) and promoter group(s) from the DRHP filing date – None of our promoter(s) and promoter group(s) have undertaken any transaction of shares aggregating up to 1% or more of the paid-up equity share capital of our Company from the DRHP filing date.

3. Pre- Offer Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of our Company:

Sr. No.	Name of Shareholder	Pre-Issue shareholding as at the date of Advertisement		Post-Issue shareholding as at Allotment ⁽³⁾			
		Number of Equity Shares	Share Holding (in %)	At the lower end of the price band i.e. ₹ 110/-		At the upper end of the price band i.e. ₹ 118/-	
				Number of Equity Shares	Share holding (in %)	Number of Equity Shares	Share holding (in %)
Promoters							
1	Dr. Chalasani Kuldeep Kumar (Promoter Selling shareholder)	80,87,586	48.44	78,73,186	35.71%	78,73,186	35.71%
2	Dr. Chalasani Kavitha (Promoter Selling shareholder)	16,34,737	9.79	14,91,737	6.77%	14,91,737	6.77%
3	M/s Sri Ram Medicare Private Limited (Promoter Selling shareholder)	45,87,154	27.48	44,44,154	20.16%	44,44,154	20.16%
4	Ms. Chalasani Lalitakumari	-	-	-	-	-	-
5	Ms. Chalasani Durga Aashritha	-	-	-	-	-	-
Promoter Group ⁽²⁾ NA							
Top 10 Shareholders ⁽⁴⁾							
1.	Mr. Yash Hitesh Patel	8,34,756	5.00%	8,34,756	3.79	8,34,756	3.79
2.	Ms. Yashvi Hitesh Patel	7,92,831	4.75%	7,92,831	3.60	7,92,831	3.60
3.	Ms. Sumita Mishra	3,33,892	2.00%	3,33,892	1.51	3,33,892	1.51
4.	Mr. Sadineni Raghu Teja	2,14,214	1.28%	2,14,214	0.97	2,14,214	0.97
5.	Mr. Siva Rama Krishna Prasad Atluri	83,863	0.50%	83,863	0.38	83,863	0.38
6.	Ms. Karri Mani Kumari	41,925	0.25%	41,925	0.19	41,925	0.19
7.	Mr. Swapnil Sudhakarrao Topale	41,925	0.25%	41,925	0.19	41,925	0.19
8.	Mr. Jai Ashok Shah	20,956	0.13%	20,956	0.10	20,956	0.10
9.	Ms. Priy Surya Prakash Mishra	20,956	0.13%	20,956	0.10	20,956	0.10
10.	NA	NA	NA	NA	NA	NA	NA
Total		1,66,94,795	100.00%	1,61,94,395	73.46%	1,61,94,395	73.46%

Notes:

1) Assuming full subscription in the Offer. The post-offer shareholding details as at allotment will be based on the actual subscription and the final Offer price and updated in the prospectus, subject to finalization of the basis of allotment. Also, this table assumes there is no transfer of shares by these shareholders between the date of the advertisement and allotment (if any such transfers occur prior to the date of prospectus, it will be updated in the shareholding pattern in the prospectus).

2) As on the date of the Red Herring Prospectus, we have total 12 (Twelve) shareholders, out of which 9 (Nine) are Public Shareholder.

BASIS FOR OFFER PRICE

The “Basis for Offer Price” on page 106 of the RHP has been updated with the above price band. Please refer to the website of the BRLM for the “Basis for Offer Price” updated with the above price band. You can scan the QR code given on the first page of this Advertisement for the chapter titled “Basis for Offer Price” on page 106 of the Red Herring Prospectus.

INDICATIVE TIMELINES FOR THE ISSUE	
Sequence of Activities	Listing within T+3 days (T is Offer Closing Date)
Application Submission by Investors	Electronic Applications (Online ASBA through 3-in-1 accounts) – Upto 5 pm on T Day. Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc) – Upto 4 pm on T Day. Electronic Applications (Syndicate Non-Institutional, Non-Individual Applications) – Upto 3 pm on T Day. Physical Applications (Bank ASBA) – Upto 1 pm on T Day. Physical Applications (Syndicate Non-Institutional, Non- Individual Applications of QIBs and NIIIs) – Upto 12 pm on T Day and Syndicate members shall transfer such applications to banks before 1 pm on T Day

Bid Modification

Validation of bid details with depositories

Reconciliation of UPI mandate transactions (Based on the guidelines issued by NPCI from time to time): Among Stock Exchanges – Sponsor Banks – NPCI and NPCI – PSPs/TPAPs** – Issuer Banks. Reporting formats of bid information, UPI analysis report and compliance timelines.

UPI Mandate acceptance time

Offer Closure

Third party check on UPI applications

Third party check on Non-UPI applications

Submission of final certificates: -For UPI from Sponsor Bank -For Bank ASBA, from all SCSBs -For syndicate ASBA

Finalization of rejections and completion of basis

Approval of basis by Stock Exchange

Issuance of fund transfer instructions in separate files for debit and unblock.

For Bank ASBA and Online ASBA – To all SCSBs For UPI ASBA – To Sponsor Bank

Corporate action execution for credit of shares

Filing of Listing Application with Stock Exchanges and issuance of trading notice

Publish allotment advertisement

Trading starts

From Issue opening date up to 5 pm on T Day

From Issue opening date up to 5 pm on T Day

On Daily basis

Merchant Bakers to submit to SEBI, sought as and when.

T day – 5 pm

T day – 4 pm for QIB and NII categories

T day – 5 pm for II and other reserved categories

On daily basis and to be completed before 9:30 AM on T+1 day.

On daily basis and to be completed before 1 pm on T+1 day.

UPI ASBA – Before 9:30 pm on T Day

All SCSBs for Direct ASBA – Before 07:30 pm on T Day

Syndicate ASBA - Before 07:30 pm on T Day

Before 6 pm on T+1 day.

Before 9 pm on T+1 day.

Intimation not later than 9:30 am on T+2 day. Completion before 2 pm on T+2 day for fund transfer. Completion before 4 pm on T+2 day for unblocking.

Initiation before 2 pm on T+2 day

Completion before 6 pm on T+2 day

Before 7:30 pm on T+2 day

On the website of Issuer, Merchant Banker and RTI - before 9 pm on T+2 day.

In newspapers - on T+3 day but not later than T+4 day

T+3 day

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects of our Company, see “History and Certain Corporate Matters” on page 173 of the Red Herring Prospectus. The Memorandum of Association of our Company is a material document for inspection in relation to the Offer. For further details, see the section “Material Contracts and Documents for Inspection” on page 409 of the Red Herring Prospectus.

LIABILITY OF MEMBERS AS PER MOA: The Liability of the members of the Company is Limited.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The authorized share capital of the Company is 2,500.00 Lakhs divided into 2,50,00,000 Equity Shares of ₹ 10/ each. The issued, subscribed and paid-up share capital of the Company before the Offer is ₹ 1,669.48 Lakhs divided into 1,66,94,795 Equity Shares of ₹ 10/ each. For details of the Capital Structure, see “Capital Structure” on the page 82 of the Red Herring Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM:

ORIGINAL SIGNATORIES			CURRENT PROMOTERS		
Name of Promoters	Face Value (₹)	No. of Shares	Name of Promoters	Face Value (₹)	No. of Shares
Raja Rao Yalamanchili	10.00	10	Dr. Chalasani Kuldeep Kumar	10.00	80,87,586
			Dr. Chalasani Kavitha	10.00	16,34,737
			M/s. Sri Ram Medicare Private Limited	10.00	45,87,154
			Ms. Chalasani Durga Aashritha	-	-
Hymavathi Yalamanchali	10.00	10	Ms. Chalasani Lalitakumari	-	-

LISTING: The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on the Emerge Platform of NSE (“NSE EMERGE”). Our Company has received an “In-principle” approval from the NSE for the listing of the Equity Shares pursuant to letter dated July 10, 2026. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of the Red Herring Prospectus has been submitted for registration to ROC on August 04, 2026 and Prospectus shall be filed with the RoC in accordance with Section 26(4) of the Companies Act, 2013.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (“SEBI”): Since the Offer is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire “Disclaimer Clause of SEBI” beginning on page 344 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF NSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE, nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the “Disclaimer Clause of NSE” beginning on page 345 of the Red Herring Prospectus.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of the Offeror and this Offer, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to “Risk Factors” on page 24 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER TO THE OFFER	REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
SMART HORIZON CAPITAL ADVISORS PVT. LTD. SMART HORIZON CAPITAL ADVISORS PRIVATE LIMITED Address: B/908, Western Edge II, Kanakia Space, Behind Metro Mall, off Western Express Highway, Magathane, Borivali East, Mumbai – 400066, Maharashtra, India. Telephone: 022-28706822 E-mail: director@shcapl.com Investors Grievance e-mail: investor@shcapl.com Contact Person: Mr. Parth Shah Website: www.shcapl.com SEBI Registration No.: INM000013183	Purva Sharegistry PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED Address: Unit No. 9, Shiv Shakti Industrial Estate, J. R. Boricha Marg, Lower Parel (East), Mumbai – 400011. Tel No: 022 - 49614132 Email: newissue@purvashare.com Website: www.purvashare.com Investor Grievance Email Id: newissue@purvashare.com Contact Person: Ms. Deepali Gaonkar SEBI Registration Number: INR000001112	PRAMODINI MEDICARE LIMITED Mr. Rushikesh Vijay Gosavi Company Secretary & Compliance Officer Address: D. No. - 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India – 520002 Tel. No.: +91- 91- 9985782727 Email: investors@pramodindiagnostics.com; Website: www.pramodindiagnostics.com Investors can contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-offer or post-offer related grievances, grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non-credit of funds by electronic mode, etc. For all offer related queries and for redressal of complaints, investors may also write to the BRLM.

Availability of Red Herring Prospectus: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein, before applying in the Offer. Full copy of the Red Herring Prospectus will be available at the website of SEBI at www.sebi.gov.in; the website of Stock Exchange at <https://www.nseindia.com/>, the website of BRLM at www.shcapl.com and website of Company at www.pramodindiagnostics.com.

Availability of Bid-Cum-Application forms: Bid-Cum-Application forms can be obtained from our Company; Pramodini Medicare Limited, Book Running Lead Manager: Smart Horizon Capital Advisors Private Limited, Application Forms can also be obtained from the Stock Exchange and list of SCSBs available on the website of SEBI at www.sebi.gov.in and website of Stock Exchange at <https://www.nseindia.com>.

Application Supported by Blocked Amount (ASBA): All investors in this Offer have to compulsorily apply through ASBA. The investors are required to fill the ASBA form and submit the same to their banks. The SCSB will block the amount in the account as per the authority contained in ASBA form. On allotment, amount will be unblocked and account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need of refund.

For more details on the Offer process and how to apply, please refer to the details given in application forms and abridged prospectus and also please refer to the chapter “Offer Procedure” on page 369 of the Red Herring Prospectus.

BANKER TO THE OFFER: Kotak Mahindra Bank Limited

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

For PRAMODINI MEDICARE LIMITED

Sd/-

Chalasani Kuldeep Kumar

Designation: Chairman & Managing Director

DIN: 03142837

Pramodini Medicare Limited is proposing, subject to market conditions and other considerations, public issue of its Equity Shares and has filed the Red Herring Prospectus with the Registrar of Companies, Andhra Pradesh on August 04, 2026. The Red Herring Prospectus is available on the website of the Book Running Lead Manager at www.shcapl.com, the website of the NSE i.e., <https://www.nseindia.com>, and website of our Company at www.pramodindiagnostics.com

Investor should note that investment in equity shares involves a high degree of risk. For details, investors should refer to and rely on the Red Herring Prospectus, including the section titled “Risk Factors” of the Red Herring Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the U.S. Securities Act (“the Securities Act”) or any state securities laws in United States and may not be issued or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as defined in Regulations under the securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933.

AdBaaZ